H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on Jan. 27.Read More
Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday.
“Following conversations with management, we are more confident that CymaBay could ink a partnership for arhalofenate (gout) in the coming six-to-12 months,” writes analyst Sa’ar Yaniv.Read More
Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday.
“In our opinion, while catalysts for the next 12-to-18 months are limited, the potential partnering of arhalofenate could be a significant driver for the shares, enhancing CymaBay’s coffers, validating the company’s approach, bridging the catalyst gap until additional data can be gleaned from MBX-8025’s HoFH and PBC programs, and increasing confidence in management’s execution,” writes analyst Sa’ar Yaniv.Read More